Inventors:
Larry Chris Blaszczak - Indianapolis IN, US
Shon Roland Pulley - Noblesville IN, US
Michael Alan Robertson - Indianapolis IN, US
Scott Martin Sheehan - Carmel IN, US
Qing Shi - Carmel IN, US
Michael Robert Wiley - Zionsville IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07D 207/04, A61K 31/40
US Classification:
514428, 514287, 514406, 5483044, 5483611, 548569
Abstract:
The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O—C-Calkyl, C-Chaloalkyl, hydroxy C-Calkyl, —C(O)R9 and —SOR9, or R7 and R8 combine to form (III), (IV); W is selected from CR1O and CR15, R1O is selected from H, halo, —C(O)NR13R14, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O—C-Calkyl and hydroxy C-Calkyl; Het is a N-linked 5-membered heteroaryl ring optionally substituted with 1-3 substituents selected from methoxy, Cl, F, CH, CF, aryl, heteroaryl, C-Calkylaryl or C-Calkylheteroaryl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.